José Luis García Giménez, professor in the Department of Physiology of the University of Valencia and principal investigator of the Epigenomics and Translational Epigenetics Research Group of the INCLIVA Health Research Institute, leads a research to develop a diagnostic and prognostic test for sepsis and septic shock, a syndrome that affects 48 million people and causes 11 million deaths per year. The project has obtained in INCLIVA a funding of 30,000 euros from the Foundation for Innovation and Prospective in Health in Spain (FIPSE).
With this rapid diagnostic test, sepsis patients can be identified in less than an hour. The project Valorisation and internationalisation by HistShock, an IVD test for the diagnosis and prognosis of sepsis and septic shock, aims to make available to clinicians a tool that will allow them to detect sepsis very quickly, which will increase the survival of those who may suffer from this syndrome.
Sepsis is a condition caused by the uncontrolled response of the body to an infection, which causes organic damage and can ultimately cause the death of the patient. The diagnosis and prognosis of patients is not easy, since no test quickly and specifically identifies the initial stages of sepsis, which reduces the success of therapeutic strategies, increases hospital costs and mortality. In addition, to obtain the results of these tests, between 24 and 72 hours are required, which delays the diagnosis and increases the risk of death in the patient and, if he survives, serious sequelae that may lead to a new hospitalisation.
Links:
